CO6321162A2 - Una vacuna que comprende una cantidad inmunogenica de un antigeno en somastatina y un adyuvante - Google Patents

Una vacuna que comprende una cantidad inmunogenica de un antigeno en somastatina y un adyuvante

Info

Publication number
CO6321162A2
CO6321162A2 CO10160849A CO10160849A CO6321162A2 CO 6321162 A2 CO6321162 A2 CO 6321162A2 CO 10160849 A CO10160849 A CO 10160849A CO 10160849 A CO10160849 A CO 10160849A CO 6321162 A2 CO6321162 A2 CO 6321162A2
Authority
CO
Colombia
Prior art keywords
somastatina
understands
vaccine
antigen
assistant
Prior art date
Application number
CO10160849A
Other languages
English (en)
Inventor
Keith N Haffer
James Larrick
Andrew R Mendelsohn
Original Assignee
Braasch Biotech Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Braasch Biotech Llc filed Critical Braasch Biotech Llc
Publication of CO6321162A2 publication Critical patent/CO6321162A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C12N9/1033—Chloramphenicol O-acetyltransferase (2.3.1.28)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)

Abstract

Se proveen composiciones y métodos para el tratamiento en la deficiencia de la hormona de crecimiento y/o factor 1 de crecimiento por el estilo de la insulina en un paciente con necesidad de tal tratamiento. Las composiciones y métodos incluyen vacunas novedosas que proveen inmunogenicidad para somatostatina y resultan en la liberación aumentada de hormona de crecimiento y/o factor 1 de crecimiento por el estilo de la insulina producidos de forma endógena.
CO10160849A 2008-06-25 2010-12-22 Una vacuna que comprende una cantidad inmunogenica de un antigeno en somastatina y un adyuvante CO6321162A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7565608P 2008-06-25 2008-06-25

Publications (1)

Publication Number Publication Date
CO6321162A2 true CO6321162A2 (es) 2011-09-20

Family

ID=41444916

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10160849A CO6321162A2 (es) 2008-06-25 2010-12-22 Una vacuna que comprende una cantidad inmunogenica de un antigeno en somastatina y un adyuvante

Country Status (15)

Country Link
US (2) US8425914B2 (es)
EP (1) EP2291194B1 (es)
JP (1) JP5627581B2 (es)
KR (1) KR101627879B1 (es)
CN (1) CN102119033B (es)
AU (1) AU2009262243B2 (es)
BR (1) BRPI0914300B8 (es)
CA (1) CA2728735A1 (es)
CO (1) CO6321162A2 (es)
IL (1) IL209829A (es)
MX (1) MX2010014078A (es)
NZ (1) NZ590010A (es)
RU (1) RU2519051C2 (es)
WO (1) WO2009158395A1 (es)
ZA (1) ZA201009127B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2430067T3 (es) 2007-03-28 2013-11-18 President And Fellows Of Harvard College Polipéptidos cosidos
JP5506792B2 (ja) 2008-06-25 2014-05-28 ブラーシュ・バイオテック・エルエルシー クロラムフェニコールアセチルトランスフェラーゼ（ｃａｔ）不完全ソマトスタチン融合タンパク質およびその使用
MX2010014078A (es) 2008-06-25 2011-04-11 Braasch Biotech Llc Composiciones y metodos para inmunogenecidad mejorada de somatostatina.
JP6181121B2 (ja) * 2009-09-30 2017-08-16 ロンザ リミテッドＬｏｎｚａ Ｌｉｍｉｔｅｄ 適応性免疫応答を向上させるためのアラビノガラクタン
EP2327411A1 (en) * 2009-11-27 2011-06-01 Lonza Ltd. Arabinogalactan as immune enhancer
US8784844B2 (en) 2009-09-30 2014-07-22 Lonza Ltd. Arabinogalactan for enhancing the adaptive immune response
KR20170058446A (ko) 2010-08-13 2017-05-26 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
RU2639523C2 (ru) 2011-10-18 2017-12-21 Эйлерон Терапьютикс, Инк. Пептидомиметические макроциклы и их применение
CA2864120A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
CA2862038C (en) 2012-02-15 2021-05-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
JP6526563B2 (ja) 2012-11-01 2019-06-05 エイルロン セラピューティクス，インコーポレイテッド 二置換アミノ酸ならびにその調製および使用の方法
US9393259B2 (en) 2013-03-21 2016-07-19 Lonza Ltd. Composition comprising arabinogalactan and polyphenols from larch trees
WO2016029013A2 (en) 2014-08-21 2016-02-25 Braasch Biotech Llc Methods for improving immunological response in vaccinated animals
MX2017003797A (es) 2014-09-24 2017-06-15 Aileron Therapeutics Inc Macrociclos peptidomimeticos y usos de los mismos.
CN107614003A (zh) 2015-03-20 2018-01-19 艾瑞朗医疗公司 拟肽大环化合物及其用途
EP3503911A4 (en) * 2016-08-26 2020-07-29 Nal Pharmaceutical Group Limited COMPOSITIONS CONTAINING HYBRID ALBUMIN PROTEIN AND ANALOGUES THEREOF, PROCESSES FOR THE PRODUCTION AND USE OF THE SAME
RU2722849C1 (ru) 2019-12-25 2020-06-04 Владимир Глебович Лунин Рекомбинантный белок GBD-SSTad-SSTad, способ его получения и применения
RU2766292C1 (ru) * 2021-08-05 2022-03-14 Федеральное государственное унитарное предприятие "Санкт-Петербургский научно-исследовательский институт вакцин и сывороток и предприятие по производству бактерийных препаратов" Федерального медико-биологического агентства (ФГУП СПбНИИВС ФМБА России) Состав вакцины против covid-19

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3919411A (en) * 1972-01-31 1975-11-11 Bayvet Corp Injectable adjuvant and compositions including such adjuvant
US4342832A (en) * 1979-07-05 1982-08-03 Genentech, Inc. Method of constructing a replicable cloning vehicle having quasi-synthetic genes
US4446235A (en) * 1982-03-22 1984-05-01 Genentech, Inc. Method for cloning human growth hormone varient genes
KR960010558B1 (ko) 1987-11-04 1996-08-02 캘리포니아 바이오테크놀로지 인코오퍼레이티드 폐포계면활성 단백질
US6316004B1 (en) * 1993-06-22 2001-11-13 T. Tikhonenko Chimeric somatostatin containing protein and encoding DNA, plasmids of expression, method for preparing chimeric protein, strain-producers, immunogenic composition, method for increasing the productivity of farm animals
AUPN999096A0 (en) * 1996-05-22 1996-06-13 Northstar Biologicals Pty Ltd Peptides, antibodies, vaccines & uses thereof
US6303584B1 (en) * 1996-11-20 2001-10-16 The University Of Montana Water soluble lipidated arabinogalactan
US6025368A (en) * 1997-02-25 2000-02-15 Celtrix Pharmaceuticals, Inc. Method for treating the symptoms of chronic stress-related disorders using IGF
US20070048860A1 (en) * 1997-10-10 2007-03-01 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Carcinoembryonic antigen (CEA) peptides
JP2002518033A (ja) * 1998-06-20 2002-06-25 ユナイティド バイオメディカル インコーポレイティド 農場動物の成長促進のための合成ソマトスタチン免疫原
MY129765A (en) * 2000-12-19 2007-04-30 Wyeth Corp Improved mycoplasma hyopneumoniae bacterin vaccine
US7018638B2 (en) * 2000-12-19 2006-03-28 Wyeth Mycoplasma hyopneumoniae bacterin vaccine
ITMI20010571A1 (it) * 2001-03-19 2002-09-19 Grisotech S A Vaccini assorbibili per via trans-mucosale
US6861410B1 (en) * 2002-03-21 2005-03-01 Chiron Corporation Immunological adjuvant compositions
PL213561B1 (pl) 2004-01-09 2013-03-29 Inst Biotechnologii I Antybiotykow Sposób otrzymywania plazmidu, plazmid oraz zastosowania
US7998930B2 (en) * 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
US7833707B2 (en) * 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
NZ561375A (en) * 2005-06-27 2011-06-30 Biovail Lab Int Srl Bupropion hydrobromide, and crystalline forms, compositions, and uses of this compound
GB0622282D0 (en) * 2006-11-08 2006-12-20 Novartis Ag Quality control methods
JP5506792B2 (ja) * 2008-06-25 2014-05-28 ブラーシュ・バイオテック・エルエルシー クロラムフェニコールアセチルトランスフェラーゼ（ｃａｔ）不完全ソマトスタチン融合タンパク質およびその使用
MX2010014078A (es) 2008-06-25 2011-04-11 Braasch Biotech Llc Composiciones y metodos para inmunogenecidad mejorada de somatostatina.

Also Published As

Publication number Publication date
EP2291194A1 (en) 2011-03-09
RU2011100105A (ru) 2012-07-20
ZA201009127B (en) 2012-02-29
US20110195080A1 (en) 2011-08-11
CN102119033B (zh) 2015-04-08
EP2291194B1 (en) 2017-02-22
KR101627879B1 (ko) 2016-06-07
BRPI0914300A2 (pt) 2015-10-13
CN102119033A (zh) 2011-07-06
NZ590010A (en) 2013-01-25
IL209829A (en) 2015-09-24
JP2011526285A (ja) 2011-10-06
AU2009262243B2 (en) 2015-01-29
WO2009158395A1 (en) 2009-12-30
EP2291194A4 (en) 2012-11-07
JP5627581B2 (ja) 2014-11-19
CA2728735A1 (en) 2009-12-30
AU2009262243A1 (en) 2009-12-30
BRPI0914300B8 (pt) 2021-05-25
MX2010014078A (es) 2011-04-11
RU2519051C2 (ru) 2014-06-10
KR20110042037A (ko) 2011-04-22
US20130149332A1 (en) 2013-06-13
BRPI0914300B1 (pt) 2021-03-23
US8425914B2 (en) 2013-04-23
IL209829A0 (en) 2011-02-28

Similar Documents

Publication Publication Date Title
CO6321162A2 (es) Una vacuna que comprende una cantidad inmunogenica de un antigeno en somastatina y un adyuvante
CL2019003264A1 (es) Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas. (divisional solicitud 201703151)
CY1123162T1 (el) Ελεγχομενης αποδεσμευσης φαρμακευτικα σκευασματα νιταζοξανιδης
AR115939A2 (es) Composición que contiene palmitoil-etanolamida ultra-micronizada
CO6331297A2 (es) Composiciones adyuvantes novedosas
ES2552651T3 (es) Composición inyectable de polidesoxirribonucleótido para el tratamiento de enfermedades osteoarticulares
BRPI0510430A (pt) composições e métodos para vacinação mucosal
UY32874A (es) Compuestos y composiciones como moduladores de la actividad de tlr
ECSP13012534A (es) Composición farmacéutica
AR078247A1 (es) Vacuna de pcsk9
CO6751287A2 (es) Composición antigénetica de micobacteria
UY32455A (es) Derivados de aminotetralina, composiciones farmacéuticas que la contienen, y sus usos en terapia
CO6561830A2 (es) Vacuna de péptido ch3 de ige
PE20151588A1 (es) Vacuna contra el virus del dengue
AR081809A1 (es) Composiciones farmaceuticas que comprenden un polipeptido que comprende al menos un motivo cxxc y antigenos heterologos y usos de las mismas
AR079890A1 (es) Estabilizacion de peliculas de oxido de zinc en composiciones bucales
MA32819B1 (fr) Vaccin combine notamment contre la coqueluche acellulaire
DOP2012000312A (es) Triazolopiridinas sustituidas
BR112015001313A2 (pt) composições de vacina
GB201113570D0 (en) Vaccine
AR089509A1 (es) Metodo para tratar la perdida osea alveolar, un implante dental, un anticuerpo antiesclerostina, un gel o matriz que comprende dicho anticuerpo y uso
CL2015001562A1 (es) Método para obtener una vacuna de mycoplasma.
BR112015021523A2 (pt) composição de uma vacina contra a tosse convulsa acelular, e, métodos para vacinar um sujeito contra a bordetella pertussis e para proteger um sujeito da tosse convulsa
BR112017022755A2 (pt) formulações de glucopiranosil lipídeo a e alérgeno a amendoim para administração sublingual
AR098985A1 (es) Composiciones prebióticas para el cuidado oral contienen un alquilglucósido

Legal Events

Date Code Title Description
FA Application withdrawn